J. Kobie

发表

Transcriptomic Determinants of Response to Pembrolizumab Monotherapy across Solid Tumor Types

Michael P. Morrissey, J. Lunceford, Chunsheng Zhang, 2021, Clinical cancer research : an official journal of the American Association for Cancer Research.

Changes in Circulating Tumor DNA Reflect Clinical Benefit Across Multiple Studies of Patients With Non–Small-Cell Lung Cancer Treated With Immune Checkpoint Inhibitors

G. Rosner, A. Chaudhuri, G. Pennello, 2022, JCO precision oncology.

1442P Association of TMB using the Foundation Medicine Companion Diagnostic (F1CDx) with efficacy of first-line pembrolizumab (pembro) or pembro plus chemotherapy (pembro + chemo) versus chemo in patients with gastric cancer (gc) from KEYNOTE-062

Y. Bang, E. Van Cutsem, J. Tabernero, 2020 .

The association of tissue tumor mutational burden (tTMB) using the Foundation Medicine genomic platform with efficacy of pembrolizumab versus paclitaxel in patients (pts) with gastric cancer (GC) from KEYNOTE-061.

Y. Bang, C. Fuchs, E. Van Cutsem, 2020 .

Association between tissue TMB (tTMB) and clinical outcomes with pembrolizumab monotherapy (pembro) in PD-L1-positive advanced NSCLC in the KEYNOTE-010 and -042 trials

J. Lunceford, M. Ayers, R. Herbst, 2019, Annals of Oncology.

The association of molecular biomarkers with efficacy of pembrolizumab versus paclitaxel in patients with gastric cancer (GC) from KEYNOTE-061.

Y. Bang, C. Fuchs, M. Mandalà, 2020 .

Associations of Tissue Tumor Mutational Burden and Mutational Status With Clinical Outcomes With Pembrolizumab Plus Chemotherapy Versus Chemotherapy For Metastatic NSCLC

J. Lunceford, M. Ayers, B. Halmos, 2022, JTO clinical and research reports.

LBA4 Association of KRAS mutational status with response to pembrolizumab monotherapy given as first-line therapy for PD-L1-positive advanced non-squamous NSCLC in Keynote-042

J. Lunceford, M. Ayers, R. Herbst, 2019 .

OA04.06 Evaluation of TMB in KEYNOTE-189: Pembrolizumab Plus Chemotherapy vs Placebo Plus Chemotherapy for Nonsquamous NSCLC

J. Lunceford, M. Ayers, E. Felip, 2019, Journal of Thoracic Oncology.

OA04.05 KEYNOTE-021: TMB and Outcomes for Carboplatin and Pemetrexed With or Without Pembrolizumab for Nonsquamous NSCLC

J. Lunceford, M. Ayers, L. Sequist, 2019, Journal of Thoracic Oncology.

Associations of Tissue Tumor Mutational Burden and Mutational Status With Clinical Outcomes in KEYNOTE-042: Pembrolizumab Versus Chemotherapy For Advanced PD-L1 Positive NSCLC.

J. Lunceford, M. Ayers, T. Mok, 2023, Annals of oncology : official journal of the European Society for Medical Oncology.

5-Year Survival Update From KEYNOTE-010: Pembrolizumab Versus Docetaxel for Previously Treated, Programmed Death Ligand 1-Positive Advanced Non-Small-Cell Lung Cancer.

R. Herbst, S. Novello, P. Baas, 2021, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

National disparities in treatment package time for resected locally advanced head and neck cancer and impact on overall survival

K. Rhodes, N. Mitra, J. Lukens, 2018, Head & neck.

Genetic sharing and heritability of paediatric age of onset autoimmune diseases

Hongzhe Li, Constantin Polychronakos, Yiran Guo, 2015, Nature Communications.

Sparse Simultaneous Signal Detection With Applications in Genomics

Julie Kobie, J. Kobie, 2016 .

Reduced Cancer Survival Among Adults With HIV and AIDS-Defining Illnesses Despite No Difference in Cancer Stage at Diagnosis

Richard D Moore, M. Gill, A. Justice, 2018, Journal of acquired immune deficiency syndromes.

Pembrolizumab (pembro) plus platinum-based chemotherapy (chemo) for metastatic NSCLC: Tissue TMB (tTMB) and outcomes in KEYNOTE-021, 189, and 407

J. Lunceford, M. Ayers, Ying Cheng, 2019, Annals of Oncology.

Restraint of the G2/M Transition by the SR/RRM Family mRNA Shuttling Binding Protein SNXAHRB1 in Aspergillus nidulans

S. Humbert, Christina M. Kelliher, K. Shingler, 2014, Genetics.